Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Inclusion Criteria

• •Age 18 years or older
• •Histologically confirmed and documented recurrent ovarian, fallopian tube, and peritoneal cancer.
• •Platinum resistant disease, defined as progression within ≤ 6 months from completion of most recent regimen and calculated from the date of the last administered dose of platinum therapy
• •Must have available archived tumor tissue OR if archived tissue is not available, willing to provide a fresh tumor biopsy
• •Must have radiologic imaging with a computerized tomography (CT) scan or magnetic resonance imaging (MRI) within 4 weeks of first dose of study drug
• •Received at least 1 but not more than 3 therapy regimens, not including maintenance or adjuvant therapy
• •Must have ovarian cancer that is measurable according to RECIST 1.1
• •ECOG performance status of 0-1
• •Normal gastrointestinal (GI), bone marrow, liver and kidney function
• •At least 28 days between termination of prior anti-cancer or hormonal therapy and administration of AVB-S6-500